🔗 Share this article

As America proceeds with historic revisions to its vaccination recommendations, a particular individual appears somewhat surprisingly: Høeg, a US-based physician and epidemiologist who initially gained attention by questioning coronavirus shots in the pandemic and has concentrated on possible deaths after COVID-19 vaccination in her short time at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Immunization Schedule

Agency leaders were set to announce sweeping changes to the childhood vaccine schedule recently, aligning the US with the Danish vaccine program, according to reports – a significant shift that would put the US at odds with many the international standard with no evidence for public health gain. The announcement has been pushed back until the next year.

Rather than the director of the vaccine center, Dr. Høeg is set to speak at the meeting. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth appointee to head the office this calendar year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad solidify control at the regulatory agency – and it suggests a greater focus upon reevaluating previously authorized immunizations at the FDA.

Høeg has often pushed for halting certain childhood vaccine recommendations in the US in order to be more in line with the Danish model, a country with nationalized medicine and a number of inhabitants roughly the population of Wisconsin’s.

In her initial statements, she has kept her attention on immunizations – usually the responsibility of Dr. Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has no obvious experience in medication creation, oversight or management, which has been standard for past leaders of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“It seems she lacks to have the necessary background” for running the CDER, remarked a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in leading a large organization. She lacks background in drug approvals.”

Previous heads of the center would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that former directors who led the center have had.”

The drug center has an vast portfolio at the agency, she stated.

“Everybody just focuses on the new drug program, but the generic program clears a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and more, and every single one must be managed,” Woodcock said. “The responsibility you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a significant leadership component to the role, which supervises more than 5,000 personnel. “It’s a huge management job, if you execute it properly,” Woodcock said.

Response and Controversial Programs

Regarding inquiries about Høeg’s credentials and whether this appointment represents increased cooperation among agency officials on vaccines, a spokesperson responded that the “questions rely on incorrect assumptions”.

“Her experience aligns with the functions of her job,” the official said, pointing to the months Dr. Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the agency head's new priority voucher program, a disputed expedited therapy clearance system that reportedly troubled her former heads. “By what process are these therapies being selected for this fast-track system? Who is making the calls?” Howard questioned. “There’s a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he said, “the agency seems to be moving towards less stringent oversight of pharmaceuticals, except for vaccines.”

Documented History on Immunizations

With immunizations, Høeg has a more established, if problematic, past, Howard observe. She released a research paper using non-validated volunteer-provided data to estimate the rate of myocarditis following COVID-19 immunization. She counseled the state of Florida top health official Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccinations are more dangerous than they are.

Included in her “wish list” for the incoming federal leadership included altering guidelines for recently developed shots and halting “non-essential” vaccines, she said post-election on a podcast. At the agency, Høeg has according to sources floated the idea of excluding teenage boys from receiving Covid vaccinations.

“She is an all-around true believer who commences with her beliefs and works backwards to fit the data in a highly disingenuous, untruthful manner,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg aligned with other dissenters, {like|